GF Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$38.2K Buy
2,033
+165
+9% +$3.33K ﹤0.01% 427
2026
Q2
$40.8K Sell
1,868
-84
-4% -$1.75K ﹤0.01% 411
2026
Q1
$45.6K Buy
1,952
+244
+14% +$5.3K ﹤0.01% 410
2025
Q4
$35.9K Sell
1,708
-145
-8% -$2.53K ﹤0.01% 439
2025
Q3
$28.5K Sell
1,853
-333
-15% -$4.36K ﹤0.01% 448
2025
Q2
$20.5K Hold
2,186
– – ﹤0.01% 501
2025
Q1
$26.9K Buy
2,186
+394
+22% +$5.56K ﹤0.01% 471
2024
Q4
$23.7K Buy
+1,792
New +$30.7K ﹤0.01% 458

Other funds holding SNDX

GF Fund Management's SNDX Position: Q3 2026 in Review

GF Fund Management increased its Syndax Pharmaceuticals (SNDX) stake by 8.8% in Q3 2026, buying an estimated $3.33K and bringing the position to 2,033 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #427.

GF Fund Management first reported a position in SNDX in Q4 2024 and has held it in 8 quarters since. The position peaked at $45.6K in Q1 2026. 237 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • GF Fund Management held 2,033 shares of Syndax Pharmaceuticals worth $38.2K as of Q3 2026.
  • GF Fund Management bought 165 Syndax Pharmaceuticals shares in Q3 2026, an estimated $3.33K.
  • Syndax Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #427 holding.
  • GF Fund Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Syndax Pharmaceuticals position peaked at $45.6K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.